TL;DR
A study analyzing Australian dispensing data reveals that a significant portion of asthma patients using inhaled corticosteroids (ICS) are also receiving high cumulative doses of oral corticosteroids (OCS), reaching levels associated with long-term toxicity. This overuse of OCS often coincides with inadequate use of controller inhalers, suggesting a critical need for improved asthma management strategies to reduce OCS reliance and its associated health risks.
What Problem Does This Paper Address?
Asthma management relies heavily on inhaled corticosteroids (ICS) for long-term control. However, for acute exacerbations or severe, persistent cases, oral corticosteroids (OCS) are sometimes necessary. While short courses of OCS are generally safe, long-term or repeated use carries significant risks of serious adverse effects, including osteoporosis, diabetes, cataracts, and cardiovascular issues. A key concern is that cumulative OCS doses exceeding 1000 mg of prednisolone-equivalent can trigger these toxicities, a threshold that can be reached with just a few courses. The problem this paper addresses is the extent to which Australian asthma patients are being exposed to these potentially toxic cumulative OCS doses, particularly among those already using ICS, and whether this overuse is linked to suboptimal controller medication use.
Methods
This study employed a retrospective cohort design, analyzing a 10% random sample of dispensing data from Australia's Pharmaceutical Benefits Scheme (PBS) between January 2014 and December 2018. The researchers identified individuals aged 12 years and older who were treated for asthma and had dispensed at least two prescriptions for ICS or ICS/long-acting beta-agonist (ICS/LABA) combinations in a single calendar year.
To define asthma patients, a combination of prescriber-submitted authority codes and a validated algorithm was used to distinguish them from patients with Chronic Obstructive Pulmonary Disease (COPD). The primary outcome measured was the cumulative dispensing of OCS (prednisolone-equivalent) over the five-year study period, with a particular focus on identifying individuals who received 1000 mg or more. Secondary outcomes included a one-year analysis (2018) of OCS dispensing, stratified by the dose and frequency of ICS/LABA controller use, and the dispensing of diabetes and osteoporosis medications in relation to OCS exposure.
Datasets
The primary dataset used was a 10% random sample of the Pharmaceutical Benefits Scheme (PBS) dispensing data for Australia, covering the period from January 1, 2014, to December 31, 2018. This dataset was validated by the Australian Bureau of Statistics as representative of the Australian population. No new benchmarks were introduced; the study utilized existing national dispensing records.
Key Insights and Ideas
- The "silent toxicity" of OCS: The study highlights that a substantial proportion of asthma patients are accumulating OCS doses that pose a significant risk of long-term toxicity, often without clear awareness or adequate mitigation strategies.
- Inadequate controller use as a driver: A critical insight is the strong association between high cumulative OCS dispensing and inadequate use of controller inhalers. This suggests that improving adherence to ICS therapy could significantly reduce the need for OCS.
- Broader health implications: The increased dispensing of diabetes and osteoporosis medications among those with high cumulative OCS exposure provides a tangible, albeit indirect, indicator of the systemic health burden associated with OCS overuse.
- General practitioners as key prescribers: The finding that general practitioners (GPs) are the primary prescribers of OCS underscores the importance of GP education and support in optimizing asthma management and reducing OCS reliance.
Key Results
- Prevalence of high OCS doses: In the study period (2014-2018), 27.9% of asthma patients using ICS were dispensed a cumulative dose of 1000 mg prednisolone-equivalent or more.
- Inadequate controller use: Among patients dispensed potentially toxic OCS doses in 2018, approximately 50% of those using high-dose ICS/LABA controllers and 68% of those using ICS alone or non-high-dose ICS/LABA controllers were considered infrequent users, indicating inadequate controller therapy.
- Comorbidities: Patients cumulatively dispensed 1000 mg or more of OCS were significantly more likely to be dispensed medications for diabetes and osteoporosis compared to those with lower OCS exposure.
- Prescriber patterns: General practitioners accounted for 76% of OCS prescriptions in 2018.
Limitations and Future Work
The authors acknowledge several limitations:
- Indirect diagnosis: The PBS database lacks comprehensive diagnostic information, meaning the classification of asthma versus COPD relied on an indirect approach, which could lead to misclassification.
- Indication for OCS: The study could not determine the specific indication for OCS dispensing, meaning some OCS might have been prescribed for conditions other than asthma.
- Pre-2014 dispensing: The analysis did not include OCS dispensing prior to 2014, potentially underestimating lifetime exposure.
- Adherence: The study could not ascertain the proportion of dispensed OCS that was actually taken by patients.
Future work should focus on developing better approaches to improve adherence to controller therapy, enhancing asthma outcomes, and minimizing OCS use and toxicity. This includes exploring strategies for detecting and improving poor adherence, implementing knowledge translation programs for prescribers, and potentially utilizing national prescribing alert systems. Further examination of OCS prescribing patterns is needed to differentiate between inadequacies in management, severe uncontrolled disease, and unnecessary prescriptions.
Summary updated